Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

Verona Pharma (NASDAQ:VRNA) reported ~$36M and $42M in net product sales for Q4 and the full year 2024, respectively, thanks to its newly launched lung disease therapy, Ohtuvayre. The FDA approved ...

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was “impressive”, with Ohtuvayre revenue ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Jan 07 6:00am ET Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights by GlobeNewswire ...